Rogel Cancer Center names Christopher Liekweg associate director for administration

Liekweg to oversee administrative functions, including NCI support grant

7:30 AM

Author | Nicole Fawcett

Rogel Cancer Center through trees
Photo courtesy Michigan Medicine

ANN ARBOR, Michigan – The University of Michigan Rogel Cancer Center has named Christopher J. Liekweg, M.B.A., CMPE, associate director for administration and chief department administrator.

Christopher J. Liekweg, M.B.A., CMPE
Christopher J. Liekweg, M.B.A., CMPE

Liekweg is a senior administrator at VCU Health, the academic medical center of Virginia Commonwealth University, where he serves as administrative director for finance and operations for the department of internal medicine. Liekweg also held the lead administrative roles for VCU Health’s department of neurology and was interim administrator for neurosurgery. He was previously executive director for radiation oncology at the University of Louisville.

As associate director for administration, Liekweg will lead administrative efforts across Rogel, including the center’s National Cancer Institute Cancer Center Support Grant, which provides $37 million in funding over the 2023-2028 period. He will oversee an administrative team that includes research administration, clinical trials support, communications, community outreach, education and training, finance and other administrative functions.

“We’re excited to bring Chris’s financial and administrative expertise to our Rogel team. He’ll bring proven leadership to these critical functions. We will benefit from his seasoned leadership in cancer-focused units at two academic medical centers  as we approach our upcoming NCI grant renewal and the launch of new strategic initiatives across our cancer center’s missions,” said Eric R. Fearon, M.D., Ph.D., director of the Rogel Cancer Center.

Liekweg will serve as a member of Rogel’s senior leadership team, which sets strategic direction for the cancer center. He will also be part of the University of Michigan Medical School’s team of chief department administrators, with a dual report to the Rogel director and the Medical School’s chief operating officer.

Liekweg replaces Julie Brabbs, M.B.A., who retired from Michigan Medicine. His appointment is effective Jan. 12, 2026.


More Articles About:

Rogel Cancer Center

Featured News & Stories

Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.
Three people stand arm in arm with backs to camera studying a wall of family mementos
Health Lab

Online resources and coaching helped people seek genetic testing for cancer

New study from researchers at the University of Michigan Rogel Cancer Center showed an online resource and phone-based coaching both helped increase rates of genetic testing.
cancer cell blue yellow
Health Lab

‘Molecular glue’ stabilizes protein that inhibits development of non-small cell lung cancer and uterine cancer

University of Michigan researchers found a new protein target PP2A and developed a drug to treat non-small cell lung cancers that have KRAS mutations.
man smiling with glasses in booth
Health Lab

Exceptional response to immunotherapy gives patient with liver cancer more milestones to celebrate

U-M Health Rogel Cancer Center used single-dose immunotherapy and transplant oncology to treat advanced hepatocellular carcinoma in a 69-year-old patient.
red blood cells going through clear tube red background
Health Lab

FDA-approved drug offers hope for patients with polycythemia vera, a rare bone marrow disorder

FDA-approved rusfertide offers new hope for polycythemia vera patients by reducing phlebotomy dependence, easing symptoms, and improving daily life.